Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 13/20 | 0.41 |
| ▸ | PYGL | P06737 | 1/20 | 0.33 |
| ▸ | PYGM | P11217 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.32 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.32 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.32 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3627780 | 0.88 | CALCRL (0.39) | CALCRLCYP3A4 | |
| SCHEMBL13015203 | 0.86 | CALCRL (0.41) | CALCRLCYP3A4 | |
| SCHEMBL13987070 | 0.82 | CALCRL (0.34) | CALCRLCYP3A4 | |
| SCHEMBL13015199 | 0.79 | CALCRL (0.33) | CALCRLCYP3A4 | |
| SCHEMBL3783469 | 0.78 | CALCRL (0.34) | CALCRLCYP3A4RPS6KB1ROCK1RPS6KA1 | |
| SCHEMBL13987068 | 0.76 | CALCRL (0.39) | CALCRLCYP3A4 | |
| SCHEMBL2213978 | 0.76 | CALCRL (0.55) | CALCRLCYP3A4 | |
| SCHEMBL15663868 | 0.76 | CALCRL (0.55) | CALCRLCYP3A4 | |
| SCHEMBL13015201 | 0.75 | CALCRL (0.39) | CALCRLCYP3A4 | |
| SCHEMBL3627128 | 0.72 | CALCRL (0.41) | CALCRLCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796260-B2 | Imidazobenzazepine CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20100324023-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2254413-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009105348-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324023-A1 | IMIDAZOBENZAZEPINE CGRP RECEPTOR ANTAGONISTS | BDKRB1, CCKBR, CALCRL | CALCRL 3/4885PYGL 4462/4885PYGM 4419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.